The role of extracorporeal photopheresis in the treatment of cutaneous T-cell lymphomas

Transfusion and Apheresis Science

Volumn 46, Issue 2, 2012, Pages 195-202

  Atta, Maria ^a   Papanicolaou, Nikolaos ^a   Tsirigotis, Panagiotis ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Cutaneous T cell lymphoma; Extracorporeal photochemotherapy; Extracorporeal photopheresis; Myocosis fungoides; Sezary syndrome

Indexed keywords

METHOXSALEN; RECOMBINANT INTERFERON;

BLOOD ANALYSIS; CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; CYTOTOXIC T LYMPHOCYTE; DISEASE CONTROL; ELECTRON BEAM; HUMAN; MONOTHERAPY; MYCOSIS FUNGOIDES; PUVA; REVIEW; SEZARY SYNDROME; TREATMENT RESPONSE;

APOPTOSIS; CELL DIFFERENTIATION; DENDRITIC CELLS; FEMALE; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; LYMPHOMA, T-CELL, CUTANEOUS; MONOCYTES; PHOTOPHERESIS; SKIN NEOPLASMS;

EID: 84858285142     PISSN: 14730502     EISSN: 18781683     Source Type: Journal    
DOI: 10.1016/j.transci.2011.10.016     Document Type: Review

References (42)

1. Edelson R.L. Photopheresis: a new therapeutic concept. Yale J Biol Med 1989, 62:565-577.
2. Edelson R., Berger C., Gasparro F., Jegasothy B., Heald P., Wintroub B., et al. Treatment of cutaneous Tcell lymphoma by extracorporeal photochemotherapy. Preliminary results. N Engl J Med 1987, 316:297-303.
3. Knobler R., Girardi M. Extracorporeal photochemoimmunotherapy in cutaneous T cell lymphomas. Ann NY Acad Sci 2001, 941:123-138.
4. Rook A.H., Suchin K.R., Kao D.M., Yoo E.K., Macey W.H., DeNardo B.J., et al. Photopheresis: clinical applications and mechanism of action. J Investig Dermatol Symp Proc 1999, 4:85-90.
5. Berger C.L., Xu A.L., Hanlon D., Lee C., Schechner J., Glusac E., et al. Induction of human tumor-loaded dendritic cells. Int J Cancer 2001, 91:438-447.
6. Hanlon D.J., Berger C.L., Edelson R.L. Photoactivated 8-methoxypsoralen treatment causes a peptide-dependent increase in antigen display by transformed lymphocytes. Int J Cancer 1998, 78:70-75.
7. Berger C.L., Longley B.J., Imaeda S., Christensen I., Heald P., Edelson R.L. Tumor-specific peptides in cutaneous T-cell lymphoma: association with class I major histocompatibility complex and possible derivation from the clonotypic T-cell receptor. Int J Cancer 1998, 76:304-311.
8. Heshmati F. Mechanisms of action of extracorporeal photochemotherapy. Transfus Apher Sci 2003, 29:61-70.
9. Lamioni A., Parisi F., Isacchi G., Giorda E., Di Cesare S., Landolfo A., et al. The immunological effects of extracorporeal photopheresis unraveled: induction of tolerogenic dendritic cells in vitro and regulatory T cells in vivo. Transplantation 2005, 79:846-850.
10. Rao V., Saunes M., Jørstad S., Moen T. Cutaneous T cell lymphoma and graft-versus-host disease: a comparison of in vivo effects of extracorporeal photochemotherapy on Foxp3+ regulatory T cells. Clin Immunol 2009, 133:303-313.
11. Zic J.A., Stricklin G.P., Greer J.P., Kinney M.C., Shyr Y., Wilson D.C., et al. Long-term follow-up of patients with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapy. J Am Acad Dermatol 1996, 35:935-945.
12. Duvic M., Hester J.P., Lemak N.A. Photopheresis therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 1996, 35:573-579.
13. Gottlieb S.L., Wolfe J.T., Fox F.E., DeNardo B.J., Macey W.H., Bromley P.G., et al. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution. J Am Acad Dermatol 1996, 35:946-957.
14. Jiang S.B., Dietz S.B., Kim M., Lim H.W. Extracorporeal photochemotherapy for cutaneous T-cell lymphoma: a 9.7-year experience. Photodermatol Photoimmunol Photomed 1999, 15:161-165.
15. Crovetti G., Carabelli A., Berti E., Guizzardi M., Fossati S., De Filippo C., et al. Photopheresis in cutaneous T-cell lymphoma: five-year experience. Int J Artif Organs 2000, 23:55-62.
16. Bisaccia E., Gonzalez J., Palangio M., Schwartz J., Klainer A.S. Extracorporeal photochemotherapy alone or with adjuvant therapy in the treatment of cutaneous T-cell lymphoma: a 9-year retrospective study at a single institution. J Am Acad Dermatol 2000, 43:263-271.
17. Evans A.V., Wood B.P., Scarisbrick J.J., Fraser-Andrews E.A., Chinn S., Dean A., et al. Extracorporeal photopheresis in Sézary syndrome: hematologic parameters as predictors of response. Blood 2001, 98:1298-1301.
18. Heald P.W., Perez M.I., Christensen I., Dobbs N., McKiernan G., Edelson R. Photopheresis therapy of cutaneous T-cell lymphoma: the Yale-New Haven Hospital experience. Yale J Biol Med 1989, 62:629-638.
19. Bouwhuis S.A., McEvoy M.T., Davis M.D. Sustained remission of Sézary syndrome. Eur J Dermatol 2002, 12:287-290.
20. Heald P., Rook A., Perez M., Wintroub B., Knobler R., Jegasothy B., et al. Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy. J Am Acad Dermatol 1992, 27:427-433.
21. Fraser-Andrews E., Seed P., Whittaker S., Russell-Jones R. Extracorporeal photopheresis in Sézary syndrome. No significant effect in the survival of 44 patients with a peripheral blood T-cell clone. Arch Dermatol 1998, 134:1001-1005.
22. Rook A.H., Prystowsky M.B., Cassin M., Boufal M., Lessin S.R. Combined therapy for Sézary syndrome with extracorporeal photochemotherapy and low-dose interferon alfa therapy. Clinical, molecular, and immunologic observations. Arch Dermatol 1991, 127:1535-1540.
23. Fimiani M., Rubegni P., De Aloe G., Andreassi L. Role of extracorporeal photochemotherapy alone and in combination with interferon alfa in the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 1999, 41:502-503.
24. Vonderheid E.C., Bigler R.D., Greenberg A.S., Neukum S.J., Micaily B. Extracorporeal photopheresis and recombinant interferon alfa 2b in Sezary syndrome. Use of dual marker labeling to monitor therapeutic response. Am J Clin Oncol 1994, 17:255-263.
25. Dippel E., Schrag H., Goerdt S., Orfanos C.E. Extracorporeal photopheresis and interferon-alpha in advanced cutaneous T-cell lymphoma. Lancet 1997, 350:32-33.
26. Olsen E.A., Bunn P.A. Interferon in the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995, 9:1089-1107.
27. Wilson L.D., Licata A.L., Braverman I.M., Edelson R.L., Heald P.W., Feldman A.M., et al. Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy. Int J Radiat Oncol Biol Phys 1995, 32:987-995.
28. Wilson L.D., Jones G.W., Kim D., Rosenthal D., Christensen I.R., Edelson R.L., et al. Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) myocosis fungoides. J Am Acad Dermatol 2000, 43:54-60.
29. Fritz T.M., Kleinhans M., Nestle F.O., Burg G., Dummer R. Combination treatment with extracorporeal photopheresis, interferon alfa and interleukin-2 in a patient with the Sézary syndrome. Br J Dermatol 1999, 140:1144-1147.
30. Rook A.H., Gottlieb S.L., Wolfe J.T., Vowels B.R., Sood S.S., Niu Z., et al. Pathogenesis of cutaneous T-cell lymphoma: implications for the use of recombinant cytokines and photopheresis. Clin Exp Immunol 1997, 107:16-20.
31. Rook A.H., Wood G.S., Yoo E.K., Elenitsas R., Kao D.M., Sherman M.L., et al. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 1999, 94:902-908.
32. Bouwhuis S.A., Markovic S.N., McEvoy M.T., Pittelkow M.R. Extracorporeal photopheresis and adjuvant aerosolized granulocyte-macrophage colony-stimulating factor for Sézary syndrome. Mayo Clin Proc 2002, 77:197-200.
33. Tsirigotis P., Pappa V., Papageorgiou S., Kapsimali V., Giannopoulou V., Kaitsa I. Extracorporeal photopheresis in combination with bexarotene in the treatment of myocosis fungoides and Sézary syndrome. Br J Dermatol 2007, 156:1379-1381.
34. Quaglino P., Fierro M.T., Rossotto G.L., Savoia P., Bernengo M.G. Treatment of advanced myocosis fungoides/Sézary syndrome with fludarabine and potential adjunctive benefit to subsequent extracorporeal photochemotherapy. Br J Dermatol 2004, 150:327-336.
35. Heald P., Perez M., McKiernan G., Christiensen I., Edelson R. Extracorporeal photochemotherapy: indications, methodology, safety aspects, side effects and long-term results. Photodermatology 1989, 6:171-176.
36. Child F.J., Mitchell T.J., Whittaker S.J., Scarisbrick J.J., Seed P.T., Russell-Jones R. A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) myocosis fungoides. Clin Exp Dermatol 2004, 29:231-236.
37. Geskin L. ECP versus PUVA for the treatment of cutaneous T-cell lymphoma. Skin Therapy Lett 2007, 12:1-4.
38. Fraser-Andrews E., Woolford A.J., Russell-Jones R., Seed P.T., Whittaker S.J. Detection of a peripheral blood T cell clone is an independent prognostic marker in Sezary syndrome. J Inv Dermatol 2000, 144:117-121.
39. Rao V., Ryggen K., Aarhaug M., Dai H.Y., Jørstad S., Moen T. Extracorporeal photochemotherapy in patients with cutaneous T-cell lymphoma: is clinical response predictable?. J Eur Acad Dermatol Venereol 2006, 20:1100-1107.
40. Scarisbrick J.J., Taylor P., Holtick U., Makar Y., Douglas K., Berlin G., et al. UK consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease. Br J Dermatol 2008, 158:659-678.
41. Miller J.D., Kirkland E.B., Domingo D.S., Scull H., Jekutis B., Dallas M., et al. Review of extracorporeal photopheresis in early-stage (IA, IB, and IIA) cutaneous T-cell lymphoma. Photodermatol Photoimmunol Photomed 2007, 23:163-171.
42. McKenna K.E., Whittaker S., Rhodes L.E., Taylor P., Lloyd J., Ibbotson S., et al. Evidence-based practice of photopheresis 1987-2001: a report of a workshop of the British Photodermatology Group and the UK Skin Lymphoma Group. Br J Dermatol 2006, 154:7-20.